บริษัท โรงงานเภสัชอตสาหกรรมุ เจเอสพี(ประเทศไทย) จํากัด(มหาชน)

JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

No. JPCS-22/009

28 June 2022

RE:

Notification of the Resolutions of the Board of Directors' Meeting No.4/2022, the Schedule of

Meeting

and the Agendas of the Extraordinary Meeting of Shareholders No.1/2022 ("EGM")

(Revised No. 1)

Attention:

President, The Stock Exchange of Thailand

JSP Pharmaceutical Manufacturing (Thailand) PCL. (the "Company") would like to inform the resolutions of the Board of Directors' Meeting No.4/2022, held on 28 June 2022, the significant resolutions of the Meeting are as follow:

1. Agreed to propose the Extraordinary Meeting of Shareholders No.1/2022 to consider and approve the change of objectives of utilisation of the proceeds received from the Initial Public Offering ("IPO") of the capital increase ordinary shares. The changes are as follows:The proposed amendment is totalled Baht 230.00 million, which derives from unutilised fund from the previous objectives. Therefore, this matter is regarded as significant change of objectives of utilisation of the proceeds so that the Company must comply with the Notification of Capital Market Supervisory Board, No. Tor Chor 39/2559 RE: Application for Approval and Granting of Approval for Offering of Newly Issued Shares Clause 38 (6) (a); if there is a change of objective of utilisation of the proceeds as stipulated in the application for approval or the registration statement to offer for sale of securities and the prospectus, the Company must obtain the approval from the Shareholders' Meeting with the votes not less than 3 of 4 of the votes of all shareholders who attend the Meeting and have the right to vote, without objection, from 10% of number of votes of the shareholders who attend the Meeting and have the right to vote. Furthermore, the Company must comply with the Notification of the Capital Supervisory Board, No. Tor Chor 71/2561 RE: Items in the Invitation to the Shareholders' Meeting of the Company with Change of Objectives of Utilisation of the Proceeds from the Registration Statement to Offer for Sale of Securities and the Draft Prospectus. The details are provided in the next page and Enclosure 1.

บริษัท โรงงานเภสัชอตสาหกรรมุ เจเอสพี(ประเทศไทย) จํากัด(มหาชน)

JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

Existing Objectives

New Objectives

Approximate

Approximate

period of

period of

Objectives of utilisation of the

Million

utilisation of

Million

utilisation of

proceeds

Baht

the proceeds

Baht

the proceeds

1. To be an investment in project of

20.00

Within the year

20.00

Within the year

new product development i.e. the

2021-2024

2021-2024

project of development and

processing of Woffia (Woffia

globosa) for commercial

manufacturing, and the project of

development and registration of

new product.

2. To be an investment in

200.00

Within the year

70.00

Within the year

development, and in making an

2021-2023

2021-2023

offer on advertising and public

relations of Company's brand to

the customers

3. To be an investment in

298.00

Within the year

223.00

Within the year

improvement and expansion of

2021-2023

2021-2023

factory (both factory in Bangkok

and factory in Lamphun Province)

4. To repay the loans from financial

100.00

Within the year

100.00

Within the year

institutions

2021

2021

5. To be the working capital of

137.38

Within the year

112.38

Within the year

business operation and for taking

2021-2022

2021-2022

any other action for the best

benefit of the Company

6. To invest in business expansion

-

-

170.00

Within the year

in form of investment in other

2022-2023

potential companies in order to

support and/or enhance the

business (1)

7. To invest in subsidiary company

-

-

60.00

Within the year

for operating business as

2022-2023

บริษัท โรงงานเภสัชอตสาหกรรมุ เจเอสพี(ประเทศไทย) จํากัด(มหาชน)

JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

Existing Objectives

New Objectives

Approximate

Approximate

period of

period of

Objectives of utilisation of the

Million

utilisation of

Million

utilisation of

proceeds

Baht

the proceeds

Baht

the proceeds

Innovation Center, and the small-

scale factory for manufacturing of

the Dietary Supplements and

Cosmetics

Total

755.38

755.38

(1)(2)

Remark::(1) The Company is considering investment potential and then will propose the Board of Directors to consider and ensure that the Company will have the best benefits prior enter into the transaction. In addition, the Company will comply with the Notification of Capital Market Supervisory Board, No. Tor Chor 20/2551 RE: Rules on Entering into Material Transactions Deemed as Acquisition or Disposal of Assets and the Notification of the Board of Governors of the Stock Exchange of Thailand RE: Disclosure of Information and Practice of the Listed Companies regarding the Acquisition and Sale/Distribution of Assets B.E. 2547 (2004), including the amendments. Furthermore, the Company will comply with the Notification of Capital Market Supervisory Board, No. Tor Chor 21/2551 RE: Rules on Connected Transactions and the Notification of the Board of Governors of the Stock Exchange of Thailand RE: Disclosure of Information and Practice of the Listed Companies regarding the Connected Transaction B.E.2546 (2003), including the amendments.

  1. theTheproceeds received after deducting by necessary expenses of the Initial Public Offering ("IPO")

2. Approved the establishment of a new subsidiary company according to the details as follow:

The date on which the Board of

28

June 2022

Directors passed its resolution

The expected date of the

Within August 2022

establishment of subsidiary

company

Company name

Caresutic Company Limited

Objectives

To generate revenue and profit apart from core business

Nature of business operation

(1)

Innovation Center for research and development of the

dietary supplements and cosmetics

(2)

Small-scale factory for manufacturing of the dietary

supplements and cosmetics

บริษัท โรงงานเภสัชอตสาหกรรมุ เจเอสพี(ประเทศไทย) จํากัด(มหาชน)

JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

Registered capital, number of

Baht 5.00 million, divided to be 50,000 shares, with a par

shares and par value

value of Baht 100 per share

Shareholding proportion

The Company will hold 99.99% of ownership interest of its

registered capital

Names of directors

(1)

Mrs. Jintana Santipisud

(2)

Mr. Sitthichai Daengprasert

(3)

Ms. Jirada Daengprasert

Source of fund for establishment

The Company's working capital

of subsidiary company

The aforementioned transaction does not meet the criteria that action must be taken in accordance with the regulations of the Notification of Capital Market Supervisory Board, No. Tor Chor 20/2551, and it does not the connected transaction. However, if, in the future, the subsidiary company increases its capital or invests more in its business and such source of fund derives from the proceeds received from the IPO, the Company must be approved by the Shareholders' Meeting with the votes not less than 3 of 4 of the votes of all shareholders who attend the Meeting and have the right to vote, without objection, from 10% of number of votes of the shareholders who attend the Meeting and have the right to vote. In this regard, the Board of Directors' Meeting No. 4/2022 dated 28 June 2022 had a resolution to fix the Extraordinary Shareholder Meeting No. 1/2022 on 16 August 2022 to consider and approve the change of objectives of utilisation of the proceeds received from IPO. In addition, the Company will comply with the Notification of Capital Market Supervisory Board, No. Tor Chor 20/2551, and the Notification of the Stock Exchange of Thailand Board of Governors, RE: Disclosure of Information and Practice of the Listed Companies regarding the Acquisition and Sale/Distribution of Assets B.E. 2547 (2004), including the amended Notifications, and the Notification of Capital Market Supervisory Board, No. Tor Jor. 21/2551, including the Notification of the Stock Exchange of Thailand Board of Governors, RE: Disclosure of Information and Practice of the Listed Companies regarding the Connected Transaction B.E.2546 (2003) including the amended Notifications.

3. Agreed to propose the Extraordinary Meeting of Shareholders No.1/2022 to consider and approve the issuing of Warrant No. 1 to purchase the Company's capital increase shares ("JP-W1") in the number not exceeding 227,500,000 shares to be allotted to the existing shareholders according to the shareholding proportion, with free-of-charge, whose allotment proportion of 2 existing ordinary shares per 1 unit of JP-W1 Warrant (in the event that there are fractions based upon the calculation according to such warrant allotment proportion, such fractions must be rounded off) Term of the warrant is 2 years from the issuing date and the offering date of the warrant, and Exercise Ratio is 1 unit of Warrant per

บริษัท โรงงานเภสัชอตสาหกรรมุ เจเอสพี(ประเทศไทย) จํากัด(มหาชน)

JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

1 ordinary share of the Company (unless there is the right adjustment according to the right adjustment conditions). The details of JP-W1 appeared in Enclosure 12.

In regard to the issuing of the aforementioned warrant, the Board of Directors and/or the President, and/or the persons who are assigned by the Board of Directors and/or the President shall have authority toa determine or amend the rules, conditions, terms of right and other details of issuing and allotting the Warrant of the Company's ordinary shares No. 1 (JP-W1), which including but not limited to, fixing of the date of issuing and allotting of the Warrant, imposing of the conditions and other details relating to the adjustment of Exercise Price and Exercise Ratio, negotiation, entering into agreement, and signing in various relevant documents and contracts, filing document, request for waiver and other evidences. And to have authority to take any necessary action or relating to the issuing and allotting of the Warrant of the Company's ordinary shares No. 1 (JP-W1), including registering the Warrant and ordinary shares arose from exercising the Warrant of the Company's ordinary shares No. 1 (JP-W1) to the Market of Alternative Investment (mai), including asking for permission from relevant agencies.

The Company will determine the list of the shareholders who are eligible to be allotted for JP-W1 (Record Date) on 1924August 2022. However, the aforementioned determining of rights entitlement is still uncertain, because there must have the approval of the Extraordinary Meeting of Shareholders No.1/2022 of the Company.

4. Agreed to propose the Extraordinary Meeting of Shareholders No.1/2022 to consider and approve the Company's registered capital increase, in the amount not exceeding Baht 113,750,000 (from the existing registered capital i.e. in the amount of Baht 227,500,000, divided into 455,000,000 ordinary shares, with a par value of Baht 0.50 per share), to be registered capital in amount of Baht 341,250,000, divided into 682,500,000 ordinary shares, with a par value of Baht 0.50 per share. The number of the ordinary shares increase will not exceed than 227,500,000 shares, with a par value of Baht 0.50 per share, whose details relating to the Company's capital increase appears in the Capital Increase Report Form (F53-4) (Enclosure 23). Moreover, the Shareholder meeting will consider and approve the amendment of the Company's Memorandum of Association, Clause 4. to be in line with the Company's capital increase, as follows:

"Clause 4." Registered capital

341,250,000

Baht

(Three hundred forty-one million two

hundred and fifty thousand baht)

Divided into

682,500,000

Shares

(Six hundred eighty-two million five

hundred thousand shares)

Par value of

0.50

Baht

(Fifty satang)

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

JSP Pharmaceutical Manufacturing Thailand pcl published this content on 04 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 July 2022 10:32:10 UTC.